|
Treatment patterns and outcomes in resectable early stage NSCLC: Interim analysis of a global real-world study. |
|
|
Employment - MD Anderson Cancer Center |
Stock and Other Ownership Interests - Scenexo |
Honoraria - AstraZeneca/MedImmune; BeyondSpring Pharmaceuticals |
Consulting or Advisory Role - Scenexo |
Speakers' Bureau - AstraZeneca |
Research Funding - BeyondSpring Pharmaceuticals; Nektar; STCube Pharmaceuticals Inc. |
Travel, Accommodations, Expenses - Elekta; STCube Pharmaceuticals Inc. |
|
|
Honoraria - Amgen; AstraZeneca; Lilly; Merck Serono; MSD; TAKEDA; YUHAN |
Consulting or Advisory Role - Alpha pharmaceutical; Amgen; AstraZeneca; Lilly; Merck Serono; MSD; Pfizer; TAKEDA; YUHAN |
|
|
|
Employment - RTI Health Solutions |
Research Funding - AstraZeneca |
|
|
|
|
|
|
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Jazz Pharmaceuticals; Merck; Novartis; Pfizer; Purdue Pharma; Roche; Takeda |
Research Funding - AstraZeneca |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; CStone Pharmaceuticals; Janssen; Lilly; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Orient EuroPharma; Pfizer; Roche; Takeda; TTY Biopharm |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; CStone Pharmaceuticals; Janssen; Lilly; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda |
|
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck Sharp & Dohme; Novartis; Pfizer; Roche |
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda |
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda |
Research Funding - AstraZeneca (Inst); Celgene (Inst); Takeda (Inst) |
|
|
Honoraria - AstraZeneca; BMS France; GlaxoSmithKline; MSD Oncology; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Amgen; BMS France; MSD Oncology; Novartis; OSE Immunotherapeutics; Pfizer; Sanofi/Aventis |
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS france (Inst); Boehringer Ingelheim (Inst); Chiesi (Inst); Chugai Pharma (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); OSE Immunotherapeutics (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; BMS france; BMS france; BMS France; Boehringer Ingelheim; Boehringer Ingelheim France; Lilly (Inst); MSD Oncology; MSD Oncology (Inst); Novartis; novartis France; Pfizer; Roche; Roche; Takeda |
|
|
No Relationships to Disclose |
|
|
Research Funding - AstraZeneca |
Other Relationship - Novartis |
|
|
|
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
No Relationships to Disclose |